Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6413475 | 0.90 | DRD2 (0.36) | DRD2CTSBCTSSCTSKSCN9A | |
| SCHEMBL6409117 | 0.90 | SMN1; SMN2 (0.42) | CCR5DRD2MMP1MMP9MMP13 | |
| SCHEMBL6408483 | 0.89 | CCR2 (0.44) | CCR2CCR5CTSBCTSSCTSK | |
| SCHEMBL6412914 | 0.89 | CCR2 (0.44) | CCR2CCR5CTSBCTSSCTSK | |
| Hydrochloric Acid SCHEMBL6412316 | 0.87 | CCR2 (0.40) | CCR2CCR5DRD2MMP1MMP9 | |
| SCHEMBL6409363 | 0.87 | CCR2 (0.38) | CCR2CCR5DRD2CTSBCTSS | |
| Hydrochloric Acid SCHEMBL6409803 | 0.87 | CCR2 (0.38) | CCR2CCR5DRD2MMP1MMP9 | |
| SCHEMBL6410266 | 0.87 | CCR2 (0.38) | CCR2CCR5DRD2 | |
| SCHEMBL5249697 | 0.87 | DRD2 (0.40) | CCR2CCR5DRD2MMP1MMP9 | |
| SCHEMBL6408481 | 0.85 | DRD2 (0.41) | CCR2CCR5DRD2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR2 5/4885CCR5 4/4885DRD2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.